U.S. Bid To Extend Drug-Patent Term In TPP Nations Meets Resistance
This article was originally published in PharmAsia News
The U.S. is maintaining its pressure on the other 11 Trans-Pacific Partnership nations to extend the term of patents and copyrights as part of the current negotiation round, but Brunei, Malaysia and Vietnam are resisting.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.